

Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the Department of Health

EVIDENCE SUMMARY

Among COVID-19 patients should interferon be used for treatment?

Updated by: Katherine Ruth O. Relato, MD, Natasha Ann R. Esteban-Ipac, MD, Carol Stephanie C. Tan-Lim, MD, MSc

Initial Review by: Gina Antonina S. Eubanas, MD, FPDS, GD (ClinEpi), Eva I. Bautista, MD, MSc, Howell Henrian G. Bayona, MSc, CSP-PASP

RECOMMENDATION

We recommend against the use of interferon in the treatment of COVID-19 patients. (Very low certainty of evidence; Strong recommendation)

Consensus Issues

Recent review included more participants (close to 6,000) yet, interferon still did not show any clear benefit for all-cause mortality and other critical outcomes. There is a need to emphasize the potential harm and side effects of the drug as well as its high cost.

PREVIOUS RECOMMENDATION

We suggest against the use of interferon in the treatment of hospitalized patients with moderate to critical COVID-19. (Very low certainty of evidence; Weak recommendation)

Previous consensus issues

Current evidence shows no significant benefit with using interferon for treating COVID-19 infections. The high cost this drug must be considered.

What's new in this version?

Six (6) new RCTs (Bhushan 2021, Pandit 2021, Ader 2021, Darazam 2021, Khalil 2021, and Rahmani 2020) were included in this update.

Key Findings

Nine (9) published randomized controlled clinical trials (RCTs) (N = 5,957) investigated the efficacy and safety of interferon in the treatment of COVID-19 compared to standard of care and/or placebo. Results showed significant benefit on viral negative conversion among patients given interferon, however, there was inconclusive evidence in terms of the critical outcomes such as all-cause mortality, clinical improvement, need for mechanical ventilation, progression to severe disease, ICU admission, adverse events, and serious adverse events.

Introduction

Interferons are used for treatment and control of multiple sclerosis, viral hepatitis and some hematologic malignancies. Type I interferon (IFN-I) includes interferon alpha and beta.[1] IFN-I response is the first line defense against viral infection. Evasion of interferon response leads to



viral transmission, replication and infection. Interferons modulate the response of the immune system to viruses.[2] An in-vitro study showed that IFN-I reduced viral replication, antigen expression, and viral load in SARs-CoV-2 [3], hence these are under investigation as a potential treatment for individuals with COVID-19.

Review Methods

A systematic search was done from the date of the last search on March 30, 2021 until November 5, 2021. Search was done in Medline, Cochrane Library, and Google scholar using free text, MeSH terms and advanced search using the term coronavirus infections, COVID-19, severe acute respiratory syndrome coronavirus 2, and interferon. Trials found in the COVID-NMA were included. Screening with ongoing trials was done in various trial registries. Medrxiv, chinaxiv, and biorxiv were searched for preprints. RCTs on interferon as treatment for COVID-19 compared to placebo were included. No limits were placed on age, severity and dose. In order to compute for confidence interval, we imputed 1 if a study had no event in the treatment arm.

Results

Characteristics of included studies

Nine (9) published randomized controlled clinical trials (RCTs) (N = 5,957) investigated the effectiveness of interferon among confirmed COVID-19 patients compared to placebo and/or standard of care. All the trials reviewed were also included in the COVID-NMA Living Data.[4-12] Appendix 3 summarizes the characteristics of the included studies.

The severity of the patients included were as follows: mild 1,156 (19.41%), moderate 4,259 (71.4%), moderate to severe 60 (1.01%), and severe 482 (8.09%). Five (5) studies compared interferon beta-1b to standard of care and/or placebo.[4-8] One study compared the effectiveness of interferon beta-1a plus hydroxychloroquine, lopinavir/ritonavir to interferon beta-1b plus hydroxychloroquine, lopinavir/ritonavir and to standard of care hydroxychloroquine, lopinavir/ritonavir.[9] One study compared the effectiveness of interferon beta-1b to standard of care in the treatment of COVID-19 [10], while, two (2) studies compared the effectiveness of PEG-interferon alpha-2b compared to standard of care in the treatment of COVID-19.[11-12] The standard of care included in the studies are hydroxychloroquine, lopinavir/ritonavir, atazanavir/ritonavir, steroids, IVIg, steroids, antibiotics, antipyretics, anticoagulants, and oxygen supplementation depending on the national clinical management guidelines. In three (3) RCTs [4,5,11], 1,078 patients in the IFN arm and 1,144 patients in the control group were given glucocorticoids.

Overall certainty of evidence

The overall certainty of evidence was rated very low due to very serious risk of bias, serious inconsistency, and imprecision in 4 critical outcomes (all-cause mortality, need for mechanical ventilator, clinical improvement, and serious adverse events). The included studies had a very serious risk of bias due to issues on performance bias, detection bias, attrition bias, and reporting bias. Seven out of nine trials were open label trials. The risk of bias summary is shown in Appendix 4. The GRADE evidence summary is in Appendix 5.

Outcomes

Interferon showed significant benefit on one of the important, but not critical outcome, viral negative conversion (RR 1.30, 95% CI 1.14, 1.49; $I^2 = 0\%$; 2 RCTs, 290 participants). However, interferon showed no significant benefit compared to standard of care and/or placebo in all-cause mortality (RR 1.06, 95% CI 0.91, 1.23; $I^2 = 48\%$; 9 RCTs, 5,957 participants), need for mechanical



ventilation (RR 0.97, 95% CI 0.82, 1.14; $I^2 = 0\%$; 4 RCTs, 4,307 participants), clinical improvement (RR 1.02, 95% CI 0.98, 1.06; $I^2 = 52\%$; 6 RCTs, 1,732 participants), progression to severe disease (RR 0.57, 95% CI 0.23, 1.42; 1 RCT, 98 participants), ICU admission (RR 0.77, 95% CI 0.59, 1.00; $I^2 = 46\%$; 2 RCTs, 126 participants), and duration of hospitalization (MD 2.55, 95% CI -0.92 to 6.02; 1 RCT, 81 participants). Results on <u>all cause mortality and clinical improvement also showed borderline</u> heterogeneity.

Subgroup analyses on the effect of interferon on mortality were stratified according to types of interferon used and severity (Appendix 5). Subgroup according to types of interferon used did not show significant benefit across groups, including those given interferon beta-1a (RR 0.91, 95% CI 0.61, 1.36; $I^2 = 53\%$; 6 RCTs, 5,571 participants); those given interferon beta-1b (RR 0.51, 95% CI 0.23, 1.12; $I^2 = 0\%$; 2 RCTs, 96 participants); and those given interferon alpha-2a (RR 2.01, 95% CI 0.36, 11.30; $I^2 = 0\%$; 2 RCTs, 290 participants). Subgroup on interferon beta-1a had borderline heterogeneity (p = 0.06).

Subgroup analysis by severity did not show significant benefit across groups, including those patients belonging to mild to severe (RR 1.12, 95% CI 0.95, 1.33; $I^2 = 0\%$; 3 RCTs, 5,167 participants), moderate (RR 2.10, 95% CI 0.40, 11.14; $I^2 = 0\%$; 2 RCTs, 290 participants), moderate to severe (RR 0.76, 95% CI 0.51, 1.14; 3 RCTs, 254 participants), and severe (RR 0.33, 95% CI 0.07, 1.53; 1 RCT, 66 participants). Results of the moderate to severe subgroup had significant heterogeneity (p = 0.04; $I^2 = 68\%$).

Safety

The rates of adverse events among patients receiving interferon (RR 1.13, 95% Cl 0.93, 1.38; $l^2 = 53\%$; p = 0.06) did not differ from those not receiving interferon. There was no significant difference in serious adverse events in interferon (RR 0.91, 95% Cl 0.71, 1.18; $l^2 = 78\%$; p = 0.001) compared to standard of care/placebo. Both adverse events and serious adverse events presented with heterogeneity. Adverse events reported were chest pain, asthenia, myalgia, headache, nausea, vomiting, hypersensitivity reaction, cough, decreased oxygen saturation, diarrhea, lymphopenia, and pruritus. Serious adverse events reported included acute kidney injury, nosocomial infection, septic shock, deep vein thrombosis, arrhythmia, respiratory failure, and hepatic failure.

All relevant forest plots for the analyses above are found in Appendix 6.

Recommendations from Other Groups

Regulatory Agency	Recommendation					
US-NIH Guidelines as of October 27, 2021 [13]	Recommends against the use of interferons for the treatment of patients with severe or critical COVID-19, except in a clinical trial (<i>Strength of recommendation is AIII</i>) and states that there are insufficient data to recommend either for or against the use of interferon beta for the treatment of early (i.e., <7 days from symptom onset) mild and moderate COVID-19.					

Table 1. Summary of Recommendations from Other Groups



Australian Guideline on COVID- 19 as of November 3, 2021 [14]	Recommends against the use interferons the treatment of COVID-19 except in the context of randomized trials. (Moderate priority recommendation and will be updated when new evidence becomes available)			
WHO Living Guidelines as of September 24, 2021 [15]	No statement on the use of interferons for the treatment o			
Infectious Diseases Society of America (IDSA) as of November 18, 2021 [16]	COVID-19.			

Research Gaps

As of November 5, 2021, there are 23 ongoing trials on interferon alpha and interferon beta registered on *clinicaltrials.gov*, EU Clinical Trials Register, and WHO International Clinical Trials Registry Platform (Appendix 9). One of the trials was terminated, two trials are already on Phase 3 and two trials are on Phase 4.



References

- [1] Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Research. 2020;178:;104791. https://doi.org/10.1016/j.antiviral.2020.104791.
- [2] Huang Y, Dai H, Ke R. Principles of Effective and Robust Innate Immune Response to Viral Infectios: A multiplex Network Analysis. 2019. https://doi.org/10.3389/fimmu.2019.01736
- [3] Lokugamage KG, Hage A, Schindewolf C, Rajsbaum R, Menachery VD. Preprint: SARS-COV-2 is sensitive to type I interferon pretreatment. 2020. https://doi.org/10.1101/2020.03.07.982264
- [4] Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al. Repurposed Antiviral Drugs for Covid-19 Interim WHO Solidarity Trial Results. N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2. PMID: 33264556; PMCID: PMC7727327.
- [5] Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, Kazemzadeh H, Yekaninejad MS. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e01061-20. doi: 10.1128/AAC.01061-20. PMID: 32661006; PMCID: PMC7449227.
- [6] Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Inhaled Interferon Beta COVID-19 Study Group. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021 Feb;9(2):196-206. doi: 10.1016/S2213-2600(20)30511-7. Epub 2020 Nov 12. PMID: 33189161; PMCID: PMC7836724. (Synairgen SG016 Phase 2 trial SNG001)
- [7] Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, et al. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clinical Microbiology and Infection. 2021 May 26;S1198-743X(21)00259-7. doi: 10.1016/j.cmi.2021.05.020.
- [8] Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalized adults with COVID-19: a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021:S2213-2600(21)00384-2
- [9] Darazam IA, Shokouhi S, Pourhoseingholi MA, Irvani SSN, Mokhtari M, Shabani M, et. al. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Nature Portfolio. 2021:11;8059
- [10] Rahmani H, Davoudi-Monfared ED, Nourian A, Hossein K, Hajizadeh N, Jalalabadi NZ, et. Al. Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial. Internmational Immunopharcology 2020. 88; 106903
- [11] Bhushan S, Wanve S, Koradia P, Bhomia V, Soni P, Chakraborty S, et al. Efficacy and Safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study. International Journal of Infectious Disease. 2021:111; 281-287



- [12] Pandit A, Bhalani N, Bhushan S, Koradia P, Gargiya S, Bhomia V, Kansagra K. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, rendomized controlled open-label study. International Journal of Infectious Disease. 2021:105; 516-521
- [13] COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines: National Institutes of Health; 2021. Available from: https://www.covid19treatmentguidelines.nih.gov/
- [14] Coronavirus Disease 2019 (COVID-19): Communicable Disease Network Australia National Guidelines for Public Health Units. 2021;5.1. Available from: https://www1.health.gov.au/
- [15] World Health Organization. [Internet]. Therapeutics and COVID-19 Living Guidelines. [updated 2021 Sept 24]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2.
- [16] Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. [Internet]. Infectious Diseases Society of America 2021; Version 5.2.0. [updated 2021 Sept 21]. Available from: https://www.idsociety.org/practiceguideline/covid-19-guideline-treatment-and-management/



Appendix 1. Evidence to Decision Table

Table	1. Summary of	initial judgements	prior to the panel	discussion ($N = 5$)

FACTORS		, ,	JUDGEMENT (N = 5			,	RESEARCH EVIDENCE/ADDITIONAL CONSIDERATIONS
Problem	No (1)	Yes (4)					
Benefits	Large	Moderate	Small (5)	Uncertain			Interferon showed no significant benefit compared to standard of care and/or placebo in all- cause mortality (RR 1.06, 95% CI 0.91-1.23), need for mechanical ventilation (RR 0.97, 95% CI 0.82-1.14), clinical improvement (RR 1.02 95% CI 0.981.06), progression to severe disease (RR 0.57, 95% CI 0.23-1.42), ICU admission (RR 0.77, 95% CI 0.59-1.00), and duration of hospitalization (MD 2.55, 95% CI -0.92 – 6.02). Interferon showed significant benefit on one of the important, but not critical outcome, viral negative conversion (RR 1.30, 95% CI 1.14-1.49).
Harm	Large (1)	Small (2)	Uncertain (2)				Interferon showed no significant difference in the risk for adverse events (RR 1.13, 95% CI 0.93-1.38) and serious adverse events (RR 0.91, 95% CI 0.71-1.18).
Certainty of Evidence	High	Moderate	Low (2)	Very low (3)			The overall certainty of evidence rated very low due to very serious risk of bias, serious inconsistency and imprecision in 4 critical outcomes.
Balance of effects	Favors drug	Does not favor drug (3)	Uncertain (2)				Interferon showed no potential harm since there is no significant difference in the adverse event and serious adverse event. With the balance favoring benefit in the viral negative conversion.
Values	Important uncertainty or variability (2)	Possibly important uncertainty or variability (3)	Possibly NO important uncertainty or variability	No important uncertainty or variability			
Resources Required	Uncertain	Large cost (5)	Moderate Cost	Negligible cost	Moderate savings	Large savings	Large cost amounting to P19,144.55 to P463,650.00 for the total cost of treatment per patient
Certainty of evidence of required resources	No included studies (5)	Very low	Low	Moderate	High		
Cost effectiveness	No included studies (5)	Favors the comparison	Does not favor either the intervention or the comparison	Favors the intervention			
Equity	Uncertain (4)	Reduced (1)	Probably no impact	Increased			
Acceptability	Uncertain (3)	No (2)	Yes				
Feasibility	Uncertain (2)	No (2)	Yes (1)				



Appendix 2. Search Yield and Results

DATADAGE		DATE AND	RESULTS		
DATABASE	SEARCH STRATEGY / SEARCH TERMS	TIME OF SEARCH	Yield	Eligible	
Medline	{"Coronavirus Infections"[Mesh] OR "Coronavirus"[Mesh] OR coronavirus OR novel coronavirus OR NCOV OR "COVID-19" [Supplementary Concept] OR covid19 OR covid 19 OR covid-19 OR "severe acute respiratory syndrome coronavirus 2" [Supplementary Concept] OR severe acute respiratory syndrome coronavirus 2 OR SARS2 OR SARS 2 OR SARS COV2 OR SARS COV 2 OR SARS-COV-2} AND Interferon AND randomized	10/31/2021 3:20PM	188	12	
CENTRAL	MeSH descriptor: [Coronaviridae Infections] explode all trees OR MeSH descriptor: [Coronavirus] explode all trees OR coronavirus OR novel coronavirus OR NCOV OR covid19 OR covid 19 OR covid-19 OR severe acute respiratory syndrome coronavirus 2 OR SARS2 OR SARS 2 OR SARS COV2 OR SARS COV 2 OR SARS-COV-2} AND MeSH descriptor: [Interferons] explode all trees	10/31/2021 5:05PM	60	17	
COVID-NMA Initiative	Interferon	10/30/2021 4:30PM	18	8	
Google Scholar	allintitle: interferon AND "COVID 19" custom range: 2020-2021	11/5/2021 4:37PM	117	8	
	•	•	•		
ClinicalTrials.gov	COVID-19 COVID-19 Pneumonia, Investigational Trials, Interferon	11/5/2021 8:30PM	44	16	
Chinese Clinical Trial Registry	Advanced: COVID, randomly sampling, interferon	11/5/2021 9:40PM	0	0	
EU Clinical Trials Register	COVID AND Interferon	11/5/2021 9:44PM	7	1	
Republic of Korea - Clinical Research Information Service	COVID AND Interferon	11/5/2021 9:46PM	0	0	
Japan Primary Registries Network/ NIPH Clinical Trials Search	COVID AND Interferon	11/5/2021 9:47PM	0	0	
CenterWatch	COVID AND Interferon	11/5/2021 9:48PM	0	0	



WHO International Clinical Trials Registry Platform	COVID AND Interferon (Filter 01/01/2021 to 11/05/2021)	11/5/2021 9:54PM	53	14
chinaxiv.org	COVID Interferon	11/5/2021 10:41PM	0	0
Medrxiv.org	COVID AND Interferon AND Randomized Filter: April 10- November 11	11/5/2021 10:47PM	180	1
Biorxiv.org	COVID AND Interferon AND Randomized Filter: April 10- November 11	11/5/2021 11:21PM	251	0



Appendix 3: Characteristics of Included Studies

Title/Author	Study design	Country	Population	Intervention Group(s)	Control	Outcomes
Pan 2020 WHO Solidarity Trial Consortium N = 4,100	Adaptive Open-label RCT	30 countries Albania, Austria, Belgium, Finland, France, Ireland, Italy, Lithuania, Luxembourg, North Macedonia, Norway, Spain, Switzerland, Argentina, Brazil, Colombia, Honduras, Peru, Egypt, India, Indonesia, Kuwait, Lebanon, Malaysia, Pakistan, Philippines, Saudi Arabia, South Africa	Hospitalized COVID- 19 patients Mild to severe	Interferon β-1a 44μg 3 doses subcutaneous over a period of 6 days OR 10μg intravenously daily for 6 days	Standard care	All-cause mortality Need for mechanical ventilation
Davoudi- Monferad 2020 N = 81	Open-label RCT	Iran	Confirmed covid-19 patients, >50% bilateral opacities on CT scan, <90% O2, hypotension, renal failure secondary to COVID-19, neurologic disorder 3 secondary to COVID-19, Thrombocytopenia Moderate to severe	Interferon β-1a 44µg/ml subcutaneously 3x a week for 2 consecutive weeks	Standard of care	All- cause mortality Clinical Improvement Time to clinical improvement Duration of hospitalization Duration of ICU stay Duration of mechanical ventilation Serious Adverse Events Adverse Events
Monk 2021 UK N = 98	Randomized, double-blind placebo- controlled, phase 2	UK	Confirmed COVID-19 patients Mild to severe	SNG001 (recombinant Interferon β -1a) 6 MIU via nebulizer once daily for up to 14 days	Placebo	All- cause mortality Clinical Improvement Progression to severe COVID-19 Serious Adverse Events Adverse Events
New Added Stu	idies (As of Nove	mber 5, 2021)	I	I		I
Ader 2021 DisCoVeRy N = 293	Open-label Adaptive RCT	France	Hospitalized confirmed COVID-19 patients, pulmonary rales or crackels, O2 sat ≤94% or requiring supplemental oxygen Moderate to severe	IFN β -1a 44 µg subcutaneously on days 1, 3 and 6 PLUS Lopinavir/ritonavir PLUS standard of care	Standard of care	Clinical improvement Day 15 Clinical improvement Day 29 Time to clinical improvement All-cause mortality Day 29 Adverse events Serious Adverse events
Kalil 2021 N = 969	Randomized, double-blind placebo- controlled	Japan, Mexico, Singapore, South Korea, USA	Hospitalized confirmed COVID-19 patients one of the following criteria of lower respiratory tract infection: radiographic infiltrates on imaging, SpO2 ≤94%, or requiring O2 supplementation Mild to severe	Interferon beta-1a 44 µg 4 doses PLUS Remdesivir	Placebo PLUS Remdesivir	Time to clinical recovery day 28 Clinical improvement Time to clinical improvement Duration of supplemental oxygen Duration of hospitalization All-cause mortality Adverse event Serious adverse event



Darazam 2021 COVIFERON N = 60	Open-label RCT	Iran	Confirmed COVID-19 patients with RTPCR and CT scan, SpO2 ≤93% OR RR ≥24 on ambient air and acute symptoms (≤14 days) Moderate to severe	Experimental 1: IFN β -1a 44 µg subcutaneous day 1, 3 and 6 PLUS Hydroxychloroquine + Lopinavir/ritonavir Experimental 2: IFN β -1b subcutaneous 0.25mg (8 MIU) PLUS Hydroxychloroquine + Lopinavir/ritonavir	Hydroxychlor oquine+Lopi navir/Ritonav ir	Time to clinical improvement All-cause mortality day 21 Need for mechanical ventilation Adverse event Serious adverse event
Rahmani 2020	Open-label RCT	Iran	Confirmed COVID-19 patient with clinical signs/symptoms of pneumonia, SpO2 <93% or Pao2/FiO2 <300 SpO2/FiO2 < 315 and lung involvement in chest imaging Severe	IFN β -1b 250mcg subcutaneously every other day for two consecutive weeks	Standard of care	Time to clinical improvement ICU admission Need for mechanical ventilation Duration of hospitalization All-cause mortality
Bhushan 2021 N = 250	Open-label RCT	India	Confirmed COVID-19 patient, Moderate SpO2 90-94% RR ≥24, Pneumonia without signs of severe pneumonia Moderate	PEG IFN α2b 1µg/kg, Subcutaneous, single dose PLUS standard of care	Standard of care	Clinical improvement Viral negative conversion Need for supplemental oxygen Need for mechanical ventilation Time to resolution of symptoms Adverse events
Pandit 2021 N= 40	Open-label RCT (Phase II)	India	Confirmed COVID-19 patient, Moderate SpO2 90-94% RR15-30, Pneumonia without signs of severe pneumonia CRP < $16mg/L$, IL-6 < $100 pg/ml$, D-dimer < $2 \mu g/ml$, interferon γ , ferritin, TNF- α , IL-1 β > upper limit of normal Moderate	PEG IFN α2b 1µg/kg, Subcutaneous, single dose PLUS standard of care	Standard of care	Clinical improvement Adverse events Need for supplemental oxygen Need for mechanical ventilation Duration of hospitalization Viral negative conversion



Appendix 4. Study Appraisal




Figure 1. Risk of bias summary table



Appendix 5: GRADE Evidence Profile Author(s): Katherine O. Relato

			Certainty a	ssessment			Nº of	patients		Effect		
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Interferon	Standard of Care	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
All-cause m	ortality											
9	randomised trials	very serious ^{a,b}	not serious	not serious	serious	none	306/2985 (10.3%)	282/2972 (9.5%)	RR 1.06 (0.91 to 1.23)	6 more per 1,000 (from 9 fewer to 22 more)		CRITICAL
Need for me	echanical ventil	ation										
4	randomised trials	very serious ^{a,b}	not serious	not serious	serious⁰	none	240/2165 (11.1%)	240/2142 (11.2%)	RR 0.97 (0.82 to 1.14)	3 fewer per 1,000 (from 20 fewer to 16 more)		CRITICAL
Clinical Imp	rovement						•					
6	randomised trials	very serious ^{a,b}	serious⁴	not serious	serious	none	693/862 (80.4%)	683/870 (78.5%)	RR 1.02 (0.98 to 1.06)	16 more per 1,000 (from 16 fewer to 47 more)		CRITICAL
Progressio	n to severe dise	ase					•					
1	randomised trials	serious ^b	not serious	not serious	seriousc.e	none	6/48 (12.5%)	11/50 (22.0%)	RR 0.57 (0.23 to 1.42)	95 fewer per 1,000 (from 169 fewer to 92 more)		CRITICAL
Adverse ev	ents											
5	randomised trials	very serious ^{a,b}	serious ^f	not serious	serious°	none	373/862 (43.3%)	315/869 (36.2%)	RR 1.13 (0.93 to 1.38)	47 more per 1,000 (from 25 fewer to 138 more)		IMPORTANT
Serious adv	verse events						•	<u>.</u>				
5	randomised trials	very serious ^{a,b}	serious	not serious	serious°	none	236/762 (31.0%)	234/739 (31.7%)	RR 0.91 (0.71 to 1.18)	28 fewer per 1,000 (from 92 fewer to 57 more)		CRITICAL
Duration of	hospitalization											
1	randomised trials	very serious ^{a,b}	not serious	not serious	serious	none	42	39	-	MD 2.55 days higher (0.92 lower to 6.02 higher)		IMPORTANT
Viral negati	ve conversion	•	•			·	•	•		• • • • •		
2	randomised trials	seriousª	not serious	not serious	not serious	none	119/140 (85.0%)	98/150 (65.3%)	RR 1.30 (1.14 to 1.49)	196 more per 1,000 (from 91 more to 320 more)		IMPORTANT
ICU admiss	ion											
2	randomised trials	seriousª	not serious	not serious	seriousc,e	none	43/73 (58.9%)	38/53 (71.7%)	RR 0.77 (0.59 to 1.00)	165 fewer per 1,000 (from 294 fewer to 0 fewer)	$\bigoplus_{LOW} \bigcirc \bigcirc$	CRITICAL

CI: confidence interval; MD: mean difference; RR: risk ratio

Explanations

a. performance and detection bias b. attrition and reporting bias




c. wide confidence interval with possibility for benefit and harm d. I2=52% e. small number of events does not reach optimal information size
 f. 12=53%
 g. 12=78%



Appendix 6. Forest Plots

	Interfe	ron	standard of	f care		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Ader DisCoVeRy 2021	17	145	12	148	4.2%	1.45 [0.72, 2.92]	
Bhushan 2021	1	20	1	20	0.4%	1.00 [0.07, 14.90]	
Darazam COVIFERON 2021	10	40	9	20	4.2%	0.56 [0.27, 1.14]	
Davoudi-Monfared 2020	8	42	17	39	6.2%	0.44 [0.21, 0.90]	_
Kalil 2021	21	487	16	482	5.6%	1.30 [0.69, 2.46]	
Monk 2020	1	48	4	50	1.4%	0.26 [0.03, 2.25]	
Pandit 2021	3	120	1	130	0.3%	3.25 [0.34, 30.82]	<u> </u>
Pan SOLIDARITY 2021	243	2050	216	2050	75.7%	1.13 [0.95, 1.34]	
Rahmani 2020	2	33	6	33	2.1%	0.33 [0.07, 1.53]	
Total (95% CI)		2985		2972	100.0%	1.06 [0.91, 1.23]	♦
Total events	306		282				
Heterogeneity: Chi ² = 15.30, df	f = 8 (P = I	0.05); I ^z	= 48%				
Test for overall effect: Z = 0.75	(P = 0.45))					0.01 0.1 1 10 100 Favours [experimental] Favours [control]




	Interfe	ron	Standard of	care		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.1.1 Interferon-Beta1a							
Ader DisCoVeRy 2021	17	145	12	148	13.9%	1.45 [0.72, 2.92]	- +
Darazam COVIFERON 2021	4	20	4	10	7.1%	0.50 [0.16, 1.59]	
Davoudi-Monfared 2020	8	42	17	39	13.5%	0.44 [0.21, 0.90]	
Kalil 2021	21	487	16	482	15.4%	1.30 [0.69, 2.46]	
Monk 2020	1	48	4	50	2.4%	0.26 [0.03, 2.25]	
Pan SOLIDARITY 2021	243	2050 2792	216	2050	29.2%	1.13 [0.95, 1.34]	<u>_</u>
Subtotal (95% CI)		2/92		2779	81.6%	0.91 [0.61, 1.36]	–
Total events	294		269				
Heterogeneity: Tau ² = 0.11; Ch			(P = 0.06); P	= 53%			
Test for overall effect: Z = 0.44	(P = 0.66)					
1.1.2 Interferon-Beta1b							
Darazam COVIFERON 2021	6	20	5	10	10.0%	0.60 [0.24, 1.49]	
Rahmani 2020	2	33	6	33	4.5%	0.33 [0.07, 1.53]	
Subtotal (95% CI)		53		43	14.6%	0.51 [0.23, 1.12]	
Total events	8		11				
Heterogeneity: Tau ² = 0.00; Ch	i ² = 0.46,	df = 1 (P = 0.50); I ² =	0%			
Test for overall effect: Z = 1.67	(P = 0.10)					
1.1.3 Interfern alpha-2a							
Bhushan 2021	1	20	1	20	1.6%	1.00 [0.07, 14.90]	
Pandit 2021	3	120	1	130	2.3%	3.25 [0.34, 30.82]	
Subtotal (95% Cl)		140		150	3.8%	2.01 [0.36, 11.30]	
Total events	4		2				
Heterogeneity: Tau ² = 0.00; Ch	i ^z = 0.43,	df = 1 (P = 0.51); I ² =	0%			
Test for overall effect: Z = 0.79	(P = 0.43)					
Total (95% CI)		2985		2972	100.0%	0.87 [0.61, 1.23]	•
Total events	306		282				
Heterogeneity: Tau ² = 0.10; Ch	ii ^z = 15.34	, df = 9	$(P = 0.08); I^2$:	= 41%			0.01 0.1 1 10 100
Test for overall effect: Z = 0.80	(P = 0.43)					Favours [experimental] Favours [control]
Test for subgroup differences:	Chi ² = 2.	66, df=	2 (P = 0.27), I	I ^z = 24.7	'%		r avours (experimental) i avours (control)

Figure 1.2 All-cause mortality subgroup based on types of interferon



	Interfe	ron	Standard of	Care		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
1.2.1 Mild to severe							
Kalil 2021	21	487	16	482	5.6%	1.30 [0.69, 2.46]	_ + •
Monk 2020	1	48	4	50	1.4%	0.26 [0.03, 2.25]	
Pan SOLIDARITY 2021	243	2050	216	2050	75.7%	1.13 [0.95, 1.34]	
Subtotal (95% CI)		2585		2582	82.7%	1.12 [0.95, 1.33]	
Total events	265		236				
Heterogeneity: $Chi^2 = 1.97$, df Test for overall effect: $Z = 1.36$: 0%				
1.2.2 Moderate							
Bhushan 2021	1	20	1	20	0.4%	1.00 [0.07, 14.90]	
Pandit 2021	3	120	1	130	0.3%	3.25 [0.34, 30.82]	
Subtotal (95% CI)		140		150	0.7%	2.10 [0.40, 11.14]	
Total events	4		2				
Heterogeneity: Chi ² = 0.43, df			:0%				
Test for overall effect: Z = 0.87	' (P = 0.38)	1					
1.2.3 Moderate to severe							
Ader DisCoVeRy 2021	17	145	12	148	4.2%	1.45 [0.72, 2.92]	-
Darazam COVIFERON 2021	10	40	9	20	4.2%	0.56 [0.27, 1.14]	
Davoudi-Monfared 2020	8	42	17	39	6.2%	0.44 [0.21, 0.90]	
Subtotal (95% CI)		227		207	14.5%	0.76 [0.51, 1.14]	•
Total events	35		38				
Heterogeneity: Chi [#] = 6.22, df Test for overall effect: Z = 1.33			68%				
1.2.4 Severe							
Rahmani 2020	2	33	6	33	2.1%	0.33 [0.07, 1.53]	
Subtotal (95% CI)		33		33	2.1%	0.33 [0.07, 1.53]	
Total events	2		6				
Heterogeneity: Not applicable							
Test for overall effect: Z = 1.41	(P = 0.16)	•					
Total (95% CI)		2985		2972	100.0%	1.06 [0.91, 1.23]	♦
Total events	306		282				
Heterogeneity: Chi ² = 15.30, c			= 48%				
Test for overall effect: Z = 0.75							Favours [experimental] Favours [control]
Test for subaroup differences	: Chi ² = 5.9	33. df =	3(P = 0.12)	r = 49.4	96		r arears texperimentall in arears teention



	Interfe	ron	Standard o	f care		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Darazam COVIFERON 2021	14	40	7	20	3.8%	1.00 [0.48, 2.08]	_
Davoudi-Monfared 2020	15	42	17	39	7.3%	0.82 [0.48, 1.41]	
Pan SOLIDARITY 2021	209	2050	210	2050	86.4%	1.00 [0.83, 1.19]	
Rahmani 2020	2	33	6	33	2.5%	0.33 [0.07, 1.53]	— — ——————————————————————————————————
Total (95% CI)		2165		2142	100.0%	0.97 [0.82, 1.14]	•
Total events	240		240				
Heterogeneity: Chi ² = 2.34, df =	= 3 (P = 0.	51); I² =	= 0%				
Test for overall effect: Z = 0.40	(P = 0.69))					0.01 0.1 1 10 100 Favours [experimental] Favours [control]



	Interfe	ron	Standard of	f care		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Ader DisCoVeRy 2021	37	145	42	148	6.1%	0.90 [0.62, 1.31]	
Bhushan 2021	112	120	118	130	16.7%	1.03 [0.96, 1.11]	+
Davoudi-Monfared 2020	31	42	23	39	3.5%	1.25 [0.91, 1.72]	+
Kalil 2021	453	487	450	482	66.5%	1.00 [0.96, 1.03]	
Monk 2020	41	48	37	51	5.3%	1.18 [0.96, 1.45]	+-
Pandit 2021	19	20	13	20	1.9%	1.46 [1.04, 2.05]	
Total (95% CI)		862		870	100.0%	1.02 [0.98, 1.06]	
Total events	693		683				
Heterogeneity: Chi ² = 10.4	4, df = 5 (i	P = 0.0	6); I² = 52%				
Test for overall effect: Z =	1.17 (P = 0	0.24)					0.01 0.1 1 10 100 Favours [experimental] Favours [control]

Figure 3. Clinical Improvement










Figure 4. ICU admission





	Interfe	ron	Standard o	f care		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Ader DisCoVeRy 2021	78	145	105	148	25.2%	0.76 [0.63, 0.91]	+
Darazam COVIFERON 2021	26	40	17	20	21.0%	0.76 [0.57, 1.02]	
Davoudi-Monfared 2020	39	42	32	39	25.6%	1.13 [0.96, 1.34]	
Kalil 2021	86	487	66	482	20.9%	1.29 [0.96, 1.73]	+ - -
Monk 2020	7	48	14	50	7.3%	0.52 [0.23, 1.18]	
Total (95% CI)		762		739	100.0%	0.91 [0.71, 1.18]	•
Total events	236		234				
Heterogeneity: Tau ² = 0.06; Cl	ni ^z = 18.27	, df = 4	(P = 0.001);	I ² = 78%			
Test for overall effect: Z = 0.68	(P = 0.50))					Favours (experimental) Favours (control)





Incidence of viral negative conversion D7





Appendix 7. Pooled Results of Trials

Outcome	Pooled/ Relative Risk	95% CI	Certainty of evidence (GRADE)
All-cause mortality (9 RCTs, N = 5,957)	1.06	0.91 to 1.23	Very Low
Need for mechanical ventilation (4 RCTs, N = 4,307)	0.97	0.82 to 1.14	Very Low
Clinical improvement (6 RCTs, N = 1,732)	1.02	0.98 to 1.06	Very Low
Progression to severe disease (1 RCT, N = 98)	0.57	0.23 to 1.42	Low
Serious adverse event (5 RCTs, N = 1,501)	0.91	0.71 to 1.18	Very Low
Adverse events (6 RCTs, N = 1,731)	1.13	0.93 to 1.38	Very Low
Duration of hospitalization (1 RCT, N = 81)	MD= 2.55	-0.92 to 6.02	Very Low
ICU admission (2 RCTs, N = 126)	0.77	0.59 to 1.00	Low
Viral negative conversion (2 RCTs, N = 290)	1.30	1.14 to 1.49	Moderate



Appendix 8. Subgroup Analysis

	Pooled Relative Risk	95% CI	Certainty of Evidence
By type of Interferon			
Interferon beta-1a	0.91	0.61 to 1.36	Very Low
(6 RCTs, n = 5,581)	0.01	0.0110 1.00	
Interferon beta-1b	0.51	0.23 to 1.12	Low
(2 RCTs, n = 106)	0.01	0.2010 1.12	2011
Interferon alpha-2a	2.01	0.36 to 11.30	Low
(2 RCTs, n = 290)	2.01	0.00 10 11.00	2011
By severity	·	·	
Mild to severe	1.12	0.95 to 1.33	Low
(3 RCTs, n = 5,167)	1.12	0.00 10 1.00	2011
Moderate	2.10	0.40 to 11.14	Low
(2 RCTs, n = 290)	2.10	0.40 10 11.14	2011
Moderate to severe	0.76	0.51 to 1.14	Very Low
(3 RCTs, n = 254)	0.70	0.01 10 1.14	
Severe	0.33	0.07 to 1.53	Low
(1 RCT, n = 66)	0.00	0.07 10 1.00	2011



Appendix 9. Characteristics of Ongoing Studies

Study Title	Patients (n)	Interventions	Outcomes	Method
 IFN-beta 1b and Remdesivir for COVID19 Recruiting Phase 2 	≥18 years hospitalized for confirmed SARS- CoV-2 infection with one of the following criteria: age 65 years or above, radiological evidence of pneumonia, oxygen desaturation <94% on room air, comorbidity including hypertension, diabetes, cardiovascular diseases, chronic obstructive lung disease, chronic liver diseases, chronic kidney diseases, malignancy, haematological diseases, rheumatological diseases, immunocompromised hosts and obesity (BMI > 30) (n=100)	Experimental: Interferon- beta 1b (16 million IU) and remdesivir 200mg IV day 1 then 100mg daily day 2-5 <u>Control:</u> Remdesivir 200mg IV day 1 then 100mg daily day 2-5	Primary: Clinical improvement (30 day)	Randomized, parallel, open label
 Dual Therapy with Interferon Beta-1b and Clofazimine for COVID- 19 Recruiting Phase 2 	18 years or above hospitalized for virologic confirmed SARS-CoV-2 infection (n=81)	Experimental 1: Interferon beta-1b (16 million IU) SC day 1-3 and Clofazamine PLUS standard of care Experimental 2: Clofazamine PLUS standard of care Control: Standard of care	Primary: Clinical alleviation of symptoms (7 days)	Randomized parallel, open label
 Clinical Study for the Treatment with Interferon-ß-1a (IFNß- 1a) of COVID-19 Patients (INTERCOP) Terminated 	Hospitalized with confirmed swab RT-PCR detection of SARS-CoV-2, X-ray and/or CT diagnosed pneumonia, Age >=18 years, Clinical status defined as 3, 4 or 5 on the 7- point ordinal scale (n=56)	Experimental: Interferon beta-1a SC 12 million IU 3 times a week at least 48 hrs apart for 2 weeks Control: Standard of care	Primary: Time to negative conversion of SARS- CoV-2 nasopharyngeal swab (day 29)	Randomized, parallel, open label
 IFN Beta-1b and Ribavirin for Covid-19 Recruiting Phase 2 	≥18 years hospitalized for confirmed SARS- CoV-2 infection. (n=96)	Experimental: Interferon beta-1b 16 million IU and Ribavirin PLUS standard of care Control: Standard of care	Primary: Clinical symptoms alleviation (7 days)	Randomized Parallel, open label
5. Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19) (IN2COVID) Recruiting Phase 2	Male subjects aged 18-50 years;In good state of health, determined by medical history, physical exam, and normal Active SARS-CoV-2 infection demonstrated by positive polymerase chain reaction (PCR) \leq 5 days at enrollment; Symptomatic of mild or moderate COVID-19 for \leq 5 days at enrollment (n=168)	Experimental 1a: Nebulized Interferon alpha 2b 2.5 million IU every 12 hours during 10 days Experimental 1b: Nebulized Interferon alpha 2b 5 million IU every 12 hours during 10 days Control Part 1: Placebo Experimental 2: nebulized Interferon alpha 2b 5 million IU every 12 hours for 10 days Control Part 2: Placebo	Primary: Treatment-emergent adverse events in healthy subjects [Time Frame: At the end of Phase 1 (11 days) Change in perception of health status measured by EQ VAS in COVID- 19 patients (28 days)	Randomized, parallel, open label
 Interferon Beta 1a in Hospitalized COVID-19 Patients (IB1aIC) 	Age \ge 50, COVID-19 Confirmed Cases, Tympanic Temperature of \ge 37.5 AND at least one of the following: Cough, Sputum	<u>Experimental:</u> Interferon-β 1a + Lopinavir / Ritonavir + Single Dose of Hydroxychloroquine	Primary: Time to clinical improvement (14 days)	Randomized, parallel, double-blind,



(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Philippine COVID-19 Li			
Enrolling by invitation Phase 4	production, nasal discharge, myalgia, headache or fatigue) on admission, Time of onset of the symptoms should be acute (Days \leq 10), SpO2 \leq 88%, Respiratory Rate \geq 24	<u>Control:</u> Lopinavir / Ritonavir + Single Dose of HydroxychloroquinePlacebo		placebo- controlled
	(n=40)			
 Trial of Inhaled Antiviral (SNG001) for SARS-CoV-2 (COVID- 19) Infection Active, not recruiting Phase 2 	 A. Hospital setting: positive virus test for SARS-CoV-2, ≥18 years of age, admitted to hospital due to the severity of their COVID 19 disease, B. Home setting: positive virus test for SARS-CoV-2, ≥50 years of age at the time of consent, non-hospitalized patients from high-risk groups, defined as ≥65-years of age, or ≥50 years of age and with any risk factors 	Experimental: SNG001(interferon beta) inhalation using the I-neb device. <u>Control:</u> Placebo	Primary: Ordinal Scale for Clinical Improvement	Randomized, parallel, double-blind placebo- controlled
	(n=820)			
 Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19) Active not recruiting Phase 2 	Male or non-pregnant females, ≥18 years of age at the time of enrolment. Has laboratory- confirmed SARS-CoV-2 infection, with SpO2 > 93% and respiratory rate <30 breaths/min,illness of any duration, and at least one of the following: Radiographic infiltrates by imaging, clinical assessment (evidence of rales/crackles or other clinical symptoms on exam)	Experimental: Pegylated Interferon-α2b 1 mcg/kg on day 1 and day 8 after safety evaluations PLUS standard of care <u>Control:</u> Standard of care	Primary: Change in Clinical status of subject on a 7-point	Randomized parallel, open- label
	(n=40)			
 Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients Not yet recruiting Early Phase 1 	Age \geq 18 years; Clinically diagnosed patients with new type of coronavirus pneumonia, including: in accordance with the criteria for suspected cases, have one of the following etiology evidence: RT-PCR, Sequencing of viral genes in respiratory specimens or blood specimens, highly homologous to known new coronavirus. The time interval between the onset of symptoms and random enrollment is within 7 days	Experimental: Recombinant human interferon α1β 10ug Bid was administered by nebulization for 10 days plus standard of care Control: Standard of care	Primary: Incidence of side effects	Randomized parallel, open label
	(n=328)			
10. Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects with CoronavirUS (HIBISCUS)	Age \geq 18 years, Positive SARS-CoV-2 test by PCR, Admission to hospital with respiratory symptoms of COVID-19 requiring hospital care and oxygen supplementation (\leq 8L/min), Symptom onset no more than 7 days prior to hospital arrival	Experimental: IFN beta-1a 10 µg as an IV bolus for 6 days while hospitalised Control: Dexamethasone	Clinical status at Day 14 (first day of study drug is Day 1) as measured by WHO 9-point ordinal scale	Randomized, parallel, double-blind
Recruiting Phase 2	(n=140)			
11. Treatment of COVID- 19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study (COV-NI) Recruiting	≥ 18 years old, confirmed SARS-CoV-2 infection as determined by PCR < 96 h (at initial diagnosis or persistent carriage <96 h), Hospitalized patient with COVID-19 requiring oxygen therapy, And targeting in phase B: under oxygen therapy such as nasal cannula/mask or non-	Experimental: Inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. Control: Placebo	Oxygen requirement score at day 0 Oxygen requirement score at day 15 Variation oxygen requirement score	Randomized, double-blind



Phase 2	invasive ventilation with paO2/FiO2 > 200 mmHg, hospitalized for less than 7 days, patients with symptoms for less than 10 days or RT-PCR (<96h) with Cycle Threshold < 25		between day 0 and day15	
12. Public Health Emergency: SOLIDARITY TRIAL Philippines Active not recruiting	Age ≥18 hospitalized with: probable or confirmed COVID-19 regardless of severity, Not already receiving any of the study drugs, without known allergy or contraindications to any of the study drugs (in the view of the physician responsible for their care), and without anticipated transfer within 72 hours to a non-study hospital.	Experimental 1: Remdesivir with SoC Experimental 2: Hydroxychloroquine with Soc Experimental 3: Lopinavir/Ritonavir with SoC Experimental 4: Acalabrutinib with SoC Experimental 5: Interferon beta-1a with SoC Control: Standard of care	Primary: All-cause mortality	Randomized parallel, adaptive open label
 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP- CAP) Recruiting Phase 4 	Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with: symptoms or signs or both that are consistent with lower respiratory tract infection AND radiological evidence of new onset consolidation Up to 48 hours after ICU admission, receiving organ support with one or more of: Non-invasive or Invasive ventilatory support; receiving infusion of vasopressor or inotropes or both	Experimental 1: Interferon B1a 10 ug IV bolus once daily for 6 days or until ICU discharge Others: Hydrocortisone, Ceftriaxone, Moxifloxacin/Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin- clavulanate, Macrolide, Oseltamivir, Lopinavir/ritonavir, Hydroxychloroquine, anakinra, tocilizumab, sarilumab, vitamin c, therapeutic anticoagulation	Primary: All-cause mortality Days alive and not receiving organ support in ICU	Randomized Factorial open label
 14. Treatments for COVID- 19: Canadian Arm of the SOLIDARITY Trial (CATCO) Recruiting Phase 2 	 ≥ 18 years of age, laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or Hospitalized at a participating centre (n= 440) 	Experimental 1: Interferon Beta 1a plus standard supportive care Experimental 2: Remdesivir plus standard supportive care Control: Standard supportive care	Primary: all-cause mortality	Randomized, parallel, open label
15. Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19 (SPRINTER) Recruiting Phase 3	Admitted to hospital due to the severity of their COVID-19, Positive virus test for SARS- CoV-2, Require oxygen therapy via nasal prongs or mask (WHO OSCI score of 4)	Experimental: inhaled interferon B (SNG001) once daily C <u>ontrol:</u> Placebo	Primary: Time to hospital discharge Time to recovery	Randomized, Parallel, Placebo controlled, double blind
15. World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments (SOLIDARITY) Not yet recruiting Phase 3	Consenting adults (age ≥18) hospitalized with definite COVID-19	Experimental 1: Remdesivir Experimental 2: Acalabrutinib Experimental 3: Interferon B1a IV 10 ug once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6 Control: Standard of Care	Primary: all-cause mortality	Randomized parallel open label
 Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 	Symptomatic and laboratory-confirmed diagnosis of COVID-19, ≥18 years old, high risk: either age ≥70 or one of the following: male; obesity (BMI ≥30); chronic	Experimental 1: Colchicine Experimental 2: ASA Experimental 3: Rivaroxaban Experimental 4: Interferon Beta 0.25mg days 1, 3, 5, 7	Primary: Outpatients: Hospital Admission or Death Inpatients: Invasive mechanical	Randomized, parallel, open- label



6778	Philippine COVID-19 Li			
2019 (COVID-19) Trial (ACTCOVID19) Recruiting Phase 3	cardiovascular, respiratory or renal disease; active cancer; diabetes; Within 7 days (ideally 72 hours) of diagnosis, or worsening clinically	Control: Standard of care	ventilation or mortality	
17. Efficacy and safety of Interferon beta-1-a in mild to moderate COVID-19 Recruiting	COVID-19, based on reverse transcriptase- polymerase chain reaction (rt-PCR), patients with mild to moderate COVID-19 within 48 hours of the onset of the symptoms	Experimental: Interferon B-a 12 million units SC very other day for 3 doses plus acetaminophen and antihistamine <u>Control:</u> Acetaminophen and antihistamine	Primary: BNody temp, DBP, level O2 saturation, PR, RR SBP	Randomized, Open label, parallel
18 Evaluation of the effect of interferon beta-1b in the treatment of COVID-19 Recruiting	Individuals over 18 years of age whose covid-19 disease has been confirmed by PCR test and clinically severely ill, o2sat below 90% despite receiving oxygen, severe bilateral pulmonary involvement	Experimental: Hydroxychloroquine and Kelatra with interferon beta-one B (at a dose of 250 micrograms or 8 million subcutaneously every other day <u>Control:</u> Hydroxychloroquine and kelatra	Primary: Changes in liver enzyme, oxygen saturation, respiratory rate, duration of hospitalization, LDH levels, Moratlity rate	Randomized, open label, parallel
19. Using interferon to treat COVID-19 Recruiting	Adult over 18 years, Clinical diagnosis of COVID-19	Experimental 1: Interferon beta plus standard of care Experimental 2: Interferon alpha plus standard of care Control: Standard of care plus placebo	Primary: Blood gas level, body temperature, respiratory rate, FiO2	Randomized, placebo controlled, double-blind
20. Efficacy evaluation of inhalation therapy (nasal spray) of Interferon Beta-1a in hospitalized Covid-19 patients	Patients who have Covid-19 based on the CT-scan or RT-PCR findings, Hospitalized patients, age between 20-65	Experimental: Interferon B1a nasal spray every 6 hours for 7 days and standard of care <u>Control:</u> Placebo	Primary: Viral negative conversion	Randomized, double blind placebo controlled
Recruiting				
21. Investigating the efficacy and safety of Interferon Beta1a nasal spray in controlling the symptoms of patients with COVID-19	18 years old or more, clinical symptoms (dry cough, shortness of breath, fever) confirm COVID-19; confirmed diagnosis of COVID- 19, less than 7 days have passed since the onset of symptoms.	Experimental: Interferon Beta 1a nasal spray 1 puff in each nostril every 6 hours, for 14 days <u>Control:</u> Standard of care	Primary: Clinical improvement	Randomized, open label, parallel
Recruiting				
22. Interferon beta 1b in COVID-19 Recruiting	All adult patients with highly suspected or confirmed COVID-19 who are candidate for hospitalization and starting therapeutic regimen with lopinavir/ritonavir and hydroxychloroquine	Experimental: Hydroxychloroquine, Iopinavir/ritonavir and interferon beta 1b <u>Control:</u> Lopinavir/ritonavir hydroxychloroquine	Primary: Clinical improvement	Randomized, open label parallel
23. Efficacy of dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19	Age 18-70 years Sever COVID19 disease with the following criteria: SPpO2 below 90% and respiratory rate higher 24 per minute; Involvement of more that 50% of lung in CT-scan	Experimental: IVIg, Dexamethasona and Interferone beta Control: Standard of care	Primary: Oxygen improvement	Randomized, open label, parallel
		1		